口腔癌及肿瘤免疫细胞中的PI3激酶通路生物标志物
研究构建123例手术切除的口腔舌鳞状细胞癌组织芯片,用免疫组化检测7种PI3激酶通路标志物在癌细胞及肿瘤浸润免疫细胞中的表达并与预后关联。免疫细胞PTEN高表达与无复发生存(HR=0.45,95%CI 0.23-0.90,P=.03)及总生存(HR=0.34,95%CI 0.15-0.76,P=.01)改善显著相关。作者认为口腔鳞癌浸润免疫细胞中PI3激酶激活(以PTEN缺失判定)具有新的不良预后作用。
要点
- 免疫细胞PTEN高表达与无复发生存改善显著相关(HR=0.45,95%CI 0.23-0.90,P=.03)。
- 免疫细胞PTEN高表达与总生存改善显著相关(HR=0.34,95%CI 0.15-0.76,P=.01)。
- 作者认为肿瘤浸润免疫细胞中PI3激酶激活(PTEN缺失)具有不良预后作用。
核心结论
- 作者发现口腔鳞癌浸润免疫细胞中PI3激酶激活(以PTEN缺失判定)具有新的不良预后作用。
- 作者认为这些发现可能与该病PI3激酶抑制剂的临床开发相关。
研究设计与样本
- 研究构建含123例口腔舌鳞状细胞癌样本的组织芯片。
- 采用免疫组化检测7种PI3激酶通路标志物:PTEN、Akt、p-Akt、mTOR、p-mTOR、survivin和Ki-67。
- 分析癌细胞或肿瘤浸润免疫细胞中标志物表达水平与预后的相关性。
主要发现
- 免疫细胞PTEN高表达与无复发生存改善显著相关(HR=0.45,95%CI 0.23-0.90,P=.03)。
- 免疫细胞PTEN高表达与总生存改善显著相关(HR=0.34,95%CI 0.15-0.76,P=.01)。
- 上述关联在单变量和多变量模型中均显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study investigated the hypothesis that phosphoinositide 3-kinase (PI3-kinase) pathway dysregulation in either head and neck cancer cells and/or tumor infiltrating immune cells would influence outcomes of patients with surgically treated oral tongue squamous cell carcinomas (SCC). METHODS: We constructed tissue microarrays containing 123 oral tongue SCC samples and performed immunohistochemistry using antibodies against 7 PI3-kinase pathway markers: phosphatase and tensin homolog (PTEN), Akt, p-Akt, mammalian target of rapamycin (mTOR), phosphorylated-mammalian target of rapamycin (p-mTOR), survivin, and Ki-67). Expression levels in cancer cells or tumor infiltrating immune cells were correlated with outcomes. RESULTS: Higher levels of PTEN expression in immune cells were significantly associated with improved recurrence-free survival (heart rate (HR) = 0.45, 95% confidence interval (CI) 0.23-0.90, P = .03), and overall survival (HR = 0.34, 95% CI 0.15-0.76, P = .01) on univariate and multicovariate models. CONCLUSIONS: We identified a novel, negative prognostic role of PI3-kinase activation (as determined by PTEN loss) in oral SCC infiltrating immune cells. These findings could be relevant for clinical development of PI-3 kinase inhibitors for this disease.
引用
- Ibrahim MY, Nunez MI, Harun N, et al. PI3-kinase pathway biomarkers in oral cancer and tumor immune cells. Head Neck. 2018. PMID: 30556200. doi:10.1002/hed.25350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。